Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Stocks rose sharply Monday after the U.S. and China said Monday they reached an agreement to temporarily slash most tariffs ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump ...